

2019 Future of Ischemia Reperfusion Injury R&D Pipeline Drugs and Companies- Analysis of Global Ischemia Reperfusion Injury Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2C9DBA8FE2BEN.html>

Date: January 2019

Pages: 100

Price: US\$ 2,199.00 (Single User License)

ID: 2C9DBA8FE2BEN

Abstracts

The global demand for Ischemia Reperfusion Injury treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Ischemia Reperfusion Injury pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Ischemia Reperfusion Injury pipeline companies from advancing their products into Phase 3 or Phase 4.

Ischemia Reperfusion Injury Report Description

The H1 2019 pipeline review report on Ischemia Reperfusion Injury pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Ischemia Reperfusion Injury pipeline compounds.

The Ischemia Reperfusion Injury pipeline guide presents information on all active drugs currently being developed for Ischemia Reperfusion Injury. The research work provides details of active therapeutic candidates in different phases including discovery,

research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Ischemia Reperfusion Injury pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Ischemia Reperfusion Injury drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Ischemia Reperfusion Injury product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Ischemia Reperfusion Injury pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Ischemia Reperfusion Injury pipeline report includes

An overview of Ischemia Reperfusion Injury disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Ischemia Reperfusion Injury pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Ischemia Reperfusion Injury pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Ischemia Reperfusion Injury pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and

company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL ISCHEMIA REPERFUSION INJURY PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Ischemia Reperfusion Injury Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Ischemia Reperfusion Injury pipeline, H1- 2019
- 3.5 Mechanism of Action wise Ischemia Reperfusion Injury Pipeline Candidates

4. ACELEROX LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 4.1 Acelerox LLC Business Profile
- 4.2 Acelerox LLC Ischemia Reperfusion Injury Drug Details
 - 4.2.1 Drug Snapshot
 - 4.2.1.1 Originator
 - 4.2.1.2 Collaborator/Co-Developer
 - 4.2.1.3 Route of Administration
 - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 4.2.1.5 Area
 - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5. AMYNDAS PHARMACEUTICALS LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 5.1 Amyndas Pharmaceuticals LLC Business Profile
- 5.2 Amyndas Pharmaceuticals LLC Ischemia Reperfusion Injury Drug Details
 - 5.2.1 Drug Snapshot
 - 5.2.1.1 Originator
 - 5.2.1.2 Collaborator/Co-Developer
 - 5.2.1.3 Route of Administration
 - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 5.2.1.5 Area
 - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6. ANGION BIOMEDICA CORP ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 6.1 Angion Biomedica Corp Business Profile
- 6.2 Angion Biomedica Corp Ischemia Reperfusion Injury Drug Details
 - 6.2.1 Drug Snapshot
 - 6.2.1.1 Originator
 - 6.2.1.2 Collaborator/Co-Developer
 - 6.2.1.3 Route of Administration
 - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 6.2.1.5 Area
 - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7. ARCH ONCOLOGY ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 7.1 Arch Oncology Business Profile

7.2 Arch Oncology Ischemia Reperfusion Injury Drug Details

7.2.1 Drug Snapshot

7.2.1.1 Originator

7.2.1.2 Collaborator/Co-Developer

7.2.1.3 Route of Administration

7.2.1.4 Orphan Drug/Fast Track/Special Designation

7.2.1.5 Area

7.2.1.6 Type of Molecular Entity

7.3 Current Status

7.4 Drug Overview

7.5 Drug Mechanism of Action

7.6 Clinical/Pre-clinical Trial Details

7.7 Latest Drug Developments

8. ARMARON BIO PTY LTD ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

8.1 Armaron Bio Pty Ltd Business Profile

8.2 Armaron Bio Pty Ltd Ischemia Reperfusion Injury Drug Details

8.2.1 Drug Snapshot

8.2.1.1 Originator

8.2.1.2 Collaborator/Co-Developer

8.2.1.3 Route of Administration

8.2.1.4 Orphan Drug/Fast Track/Special Designation

8.2.1.5 Area

8.2.1.6 Type of Molecular Entity

8.3 Current Status

8.4 Drug Overview

8.5 Drug Mechanism of Action

8.6 Clinical/Pre-clinical Trial Details

8.7 Latest Drug Developments

9. BIOMEDCORE INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

9.1 BioMedCore Inc Business Profile

9.2 BioMedCore Inc Ischemia Reperfusion Injury Drug Details

9.2.1 Drug Snapshot

9.2.1.1 Originator

9.2.1.2 Collaborator/Co-Developer

9.2.1.3 Route of Administration

- 9.2.1.4 Orphan Drug/Fast Track/Special Designation
- 9.2.1.5 Area
- 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10. BOLDER BIOTECHNOLOGY INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 10.1 Bolder Biotechnology Inc Business Profile
- 10.2 Bolder Biotechnology Inc Ischemia Reperfusion Injury Drug Details
 - 10.2.1 Drug Snapshot
 - 10.2.1.1 Originator
 - 10.2.1.2 Collaborator/Co-Developer
 - 10.2.1.3 Route of Administration
 - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 10.2.1.5 Area
 - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11. CATALYST BIOSCIENCES INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 11.1 Catalyst Biosciences Inc Business Profile
- 11.2 Catalyst Biosciences Inc Ischemia Reperfusion Injury Drug Details
 - 11.2.1 Drug Snapshot
 - 11.2.1.1 Originator
 - 11.2.1.2 Collaborator/Co-Developer
 - 11.2.1.3 Route of Administration
 - 11.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 11.2.1.5 Area
 - 11.2.1.6 Type of Molecular Entity

- 11.3 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12. CELDARA MEDICAL LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 12.1 Celdara Medical LLC Business Profile
- 12.2 Celdara Medical LLC Ischemia Reperfusion Injury Drug Details
 - 12.2.1 Drug Snapshot
 - 12.2.1.1 Originator
 - 12.2.1.2 Collaborator/Co-Developer
 - 12.2.1.3 Route of Administration
 - 12.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 12.2.1.5 Area
 - 12.2.1.6 Type of Molecular Entity
- 12.3 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13. CELLMID LTD ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 13.1 Cellmid Ltd Business Profile
- 13.2 Cellmid Ltd Ischemia Reperfusion Injury Drug Details
 - 13.2.1 Drug Snapshot
 - 13.2.1.1 Originator
 - 13.2.1.2 Collaborator/Co-Developer
 - 13.2.1.3 Route of Administration
 - 13.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 13.2.1.5 Area
 - 13.2.1.6 Type of Molecular Entity
- 13.3 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14. CFM PHARMA HOLDING BV ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

14.1 CFM Pharma Holding BV Business Profile

14.2 CFM Pharma Holding BV Ischemia Reperfusion Injury Drug Details

14.2.1 Drug Snapshot

14.2.1.1 Originator

14.2.1.2 Collaborator/Co-Developer

14.2.1.3 Route of Administration

14.2.1.4 Orphan Drug/Fast Track/Special Designation

14.2.1.5 Area

14.2.1.6 Type of Molecular Entity

14.3 Current Status

14.4 Drug Overview

14.5 Drug Mechanism of Action

14.6 Clinical/Pre-clinical Trial Details

14.7 Latest Drug Developments

15. CONATUS PHARMACEUTICALS INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

15.1 Conatus Pharmaceuticals Inc Business Profile

15.2 Conatus Pharmaceuticals Inc Ischemia Reperfusion Injury Drug Details

15.2.1 Drug Snapshot

15.2.1.1 Originator

15.2.1.2 Collaborator/Co-Developer

15.2.1.3 Route of Administration

15.2.1.4 Orphan Drug/Fast Track/Special Designation

15.2.1.5 Area

15.2.1.6 Type of Molecular Entity

15.3 Current Status

15.4 Drug Overview

15.5 Drug Mechanism of Action

15.6 Clinical/Pre-clinical Trial Details

15.7 Latest Drug Developments

16. CORLINE BIOMEDICAL AB ISCHEMIA REPERFUSION INJURY PIPELINE

DETAILS

- 16.1 Corline Biomedical AB Business Profile
- 16.2 Corline Biomedical AB Ischemia Reperfusion Injury Drug Details
 - 16.2.1 Drug Snapshot
 - 16.2.1.1 Originator
 - 16.2.1.2 Collaborator/Co-Developer
 - 16.2.1.3 Route of Administration
 - 16.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 16.2.1.5 Area
 - 16.2.1.6 Type of Molecular Entity
- 16.3 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17. FARADAY PHARMACEUTICALS ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 17.1 Faraday Pharmaceuticals Business Profile
- 17.2 Faraday Pharmaceuticals Ischemia Reperfusion Injury Drug Details
 - 17.2.1 Drug Snapshot
 - 17.2.1.1 Originator
 - 17.2.1.2 Collaborator/Co-Developer
 - 17.2.1.3 Route of Administration
 - 17.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 17.2.1.5 Area
 - 17.2.1.6 Type of Molecular Entity
- 17.3 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18. GLUCOX BIOTECH AB ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 18.1 Glucoc Biotech AB Business Profile
- 18.2 Glucoc Biotech AB Ischemia Reperfusion Injury Drug Details

- 18.2.1 Drug Snapshot
 - 18.2.1.1 Originator
 - 18.2.1.2 Collaborator/Co-Developer
 - 18.2.1.3 Route of Administration
 - 18.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 18.2.1.5 Area
 - 18.2.1.6 Type of Molecular Entity

18.3 Current Status

18.4 Drug Overview

18.5 Drug Mechanism of Action

18.6 Clinical/Pre-clinical Trial Details

18.7 Latest Drug Developments

19. ISCHEMIX INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

19.1 Ischemix Inc Business Profile

19.2 Ischemix Inc Ischemia Reperfusion Injury Drug Details

- 19.2.1 Drug Snapshot
 - 19.2.1.1 Originator
 - 19.2.1.2 Collaborator/Co-Developer
 - 19.2.1.3 Route of Administration
 - 19.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 19.2.1.5 Area
 - 19.2.1.6 Type of Molecular Entity

19.3 Current Status

19.4 Drug Overview

19.5 Drug Mechanism of Action

19.6 Clinical/Pre-clinical Trial Details

19.7 Latest Drug Developments

20. MALLINCKRODT PLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

20.1 Mallinckrodt Plc Business Profile

20.2 Mallinckrodt Plc Ischemia Reperfusion Injury Drug Details

- 20.2.1 Drug Snapshot
 - 20.2.1.1 Originator
 - 20.2.1.2 Collaborator/Co-Developer
 - 20.2.1.3 Route of Administration
 - 20.2.1.4 Orphan Drug/Fast Track/Special Designation

- 20.2.1.5 Area
- 20.2.1.6 Type of Molecular Entity
- 20.3 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21. MIRAGEN THERAPEUTICS INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 21.1 Miragen Therapeutics Inc Business Profile
- 21.2 Miragen Therapeutics Inc Ischemia Reperfusion Injury Drug Details
 - 21.2.1 Drug Snapshot
 - 21.2.1.1 Originator
 - 21.2.1.2 Collaborator/Co-Developer
 - 21.2.1.3 Route of Administration
 - 21.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 21.2.1.5 Area
 - 21.2.1.6 Type of Molecular Entity
- 21.3 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22. NOVELMED THERAPEUTICS INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 22.1 NovelMed Therapeutics Inc Business Profile
- 22.2 NovelMed Therapeutics Inc Ischemia Reperfusion Injury Drug Details
 - 22.2.1 Drug Snapshot
 - 22.2.1.1 Originator
 - 22.2.1.2 Collaborator/Co-Developer
 - 22.2.1.3 Route of Administration
 - 22.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 22.2.1.5 Area
 - 22.2.1.6 Type of Molecular Entity
- 22.3 Current Status

- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

23. OPSONA THERAPEUTICS LTD ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 23.1 Opsona Therapeutics Ltd Business Profile
- 23.2 Opsona Therapeutics Ltd Ischemia Reperfusion Injury Drug Details
 - 23.2.1 Drug Snapshot
 - 23.2.1.1 Originator
 - 23.2.1.2 Collaborator/Co-Developer
 - 23.2.1.3 Route of Administration
 - 23.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 23.2.1.5 Area
 - 23.2.1.6 Type of Molecular Entity
- 23.3 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

24. PHARMING GROUP NV ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 24.1 Pharming Group NV Business Profile
- 24.2 Pharming Group NV Ischemia Reperfusion Injury Drug Details
 - 24.2.1 Drug Snapshot
 - 24.2.1.1 Originator
 - 24.2.1.2 Collaborator/Co-Developer
 - 24.2.1.3 Route of Administration
 - 24.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 24.2.1.5 Area
 - 24.2.1.6 Type of Molecular Entity
- 24.3 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

25. PROLONG PHARMACEUTICALS LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 25.1 Prolong Pharmaceuticals LLC Business Profile
- 25.2 Prolong Pharmaceuticals LLC Ischemia Reperfusion Injury Drug Details
 - 25.2.1 Drug Snapshot
 - 25.2.1.1 Originator
 - 25.2.1.2 Collaborator/Co-Developer
 - 25.2.1.3 Route of Administration
 - 25.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 25.2.1.5 Area
 - 25.2.1.6 Type of Molecular Entity
- 25.3 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

26. PROTHIX BV ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 26.1 Prothix BV Business Profile
- 26.2 Prothix BV Ischemia Reperfusion Injury Drug Details
 - 26.2.1 Drug Snapshot
 - 26.2.1.1 Originator
 - 26.2.1.2 Collaborator/Co-Developer
 - 26.2.1.3 Route of Administration
 - 26.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 26.2.1.5 Area
 - 26.2.1.6 Type of Molecular Entity
- 26.3 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action
- 26.6 Clinical/Pre-clinical Trial Details
- 26.7 Latest Drug Developments

27. RADIKAL THERAPEUTICS INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 27.1 Radikal Therapeutics Inc Business Profile
- 27.2 Radikal Therapeutics Inc Ischemia Reperfusion Injury Drug Details
 - 27.2.1 Drug Snapshot
 - 27.2.1.1 Originator
 - 27.2.1.2 Collaborator/Co-Developer
 - 27.2.1.3 Route of Administration
 - 27.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 27.2.1.5 Area
 - 27.2.1.6 Type of Molecular Entity
- 27.3 Current Status
- 27.4 Drug Overview
- 27.5 Drug Mechanism of Action
- 27.6 Clinical/Pre-clinical Trial Details
- 27.7 Latest Drug Developments

28. SBI PHARMACEUTICALS CO LTD ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 28.1 SBI Pharmaceuticals Co Ltd Business Profile
- 28.2 SBI Pharmaceuticals Co Ltd Ischemia Reperfusion Injury Drug Details
 - 28.2.1 Drug Snapshot
 - 28.2.1.1 Originator
 - 28.2.1.2 Collaborator/Co-Developer
 - 28.2.1.3 Route of Administration
 - 28.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 28.2.1.5 Area
 - 28.2.1.6 Type of Molecular Entity
- 28.3 Current Status
- 28.4 Drug Overview
- 28.5 Drug Mechanism of Action
- 28.6 Clinical/Pre-clinical Trial Details
- 28.7 Latest Drug Developments

29. THERASOURCE LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 29.1 TheraSource LLC Business Profile
- 29.2 TheraSource LLC Ischemia Reperfusion Injury Drug Details
 - 29.2.1 Drug Snapshot
 - 29.2.1.1 Originator

- 29.2.1.2 Collaborator/Co-Developer
- 29.2.1.3 Route of Administration
- 29.2.1.4 Orphan Drug/Fast Track/Special Designation
- 29.2.1.5 Area
- 29.2.1.6 Type of Molecular Entity
- 29.3 Current Status
- 29.4 Drug Overview
- 29.5 Drug Mechanism of Action
- 29.6 Clinical/Pre-clinical Trial Details
- 29.7 Latest Drug Developments

30. TRIM-EDICINE INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 30.1 TRIM-edicine Inc Business Profile
- 30.2 TRIM-edicine Inc Ischemia Reperfusion Injury Drug Details
 - 30.2.1 Drug Snapshot
 - 30.2.1.1 Originator
 - 30.2.1.2 Collaborator/Co-Developer
 - 30.2.1.3 Route of Administration
 - 30.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 30.2.1.5 Area
 - 30.2.1.6 Type of Molecular Entity
- 30.3 Current Status
- 30.4 Drug Overview
- 30.5 Drug Mechanism of Action
- 30.6 Clinical/Pre-clinical Trial Details
- 30.7 Latest Drug Developments

31. X-IN8 BIOLOGICALS CORP ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS

- 31.1 X-In8 Biologicals Corp Business Profile
- 31.2 X-In8 Biologicals Corp Ischemia Reperfusion Injury Drug Details
 - 31.2.1 Drug Snapshot
 - 31.2.1.1 Originator
 - 31.2.1.2 Collaborator/Co-Developer
 - 31.2.1.3 Route of Administration
 - 31.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 31.2.1.5 Area

- 31.2.1.6 Type of Molecular Entity
- 31.3 Current Status
- 31.4 Drug Overview
- 31.5 Drug Mechanism of Action
- 31.6 Clinical/Pre-clinical Trial Details
- 31.7 Latest Drug Developments

20. LATEST ISCHEMIA REPERFUSION INJURY DRUG PIPELINE DEVELOPMENTS, 2019

21. APPENDIX

- 21.1 About Us
- 21.2 Sources and Methodology
- 21.3 Contact Information

I would like to order

Product name: 2019 Future of Ischemia Reperfusion Injury R&D Pipeline Drugs and Companies- Analysis of Global Ischemia Reperfusion Injury Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2C9DBA8FE2BEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2C9DBA8FE2BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970